nimotuzumab + sintilizumab

Nimotuzumab + sintilizumab is a combination immunotherapy and targeted therapy regimen being investigated for the treatment of advanced malignancies, particularly esophageal squamous cell carcinoma (ESCC). Nimotuzumab is a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR), inhibiting downstream signaling pathways involved in cell proliferation and survival. Sintilizumab is a humanized monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor, acting as a checkpoint inhibitor to restore T-cell mediated anti-tumor immunity. The combination aims to provide synergistic effects by simultaneously blocking oncogenic growth signals and enhancing the immune system's ability to recognize and destroy cancer cells. Clinical research led by institutions such as the Sixth Medical Center of PLA General Hospital has focused on evaluating this combination, often alongside chemotherapy or radiotherapy, as a first-line or later-line treatment for ESCC.

Brand names

TaixinqiTyvyt

Other names

Nimotuzumab plus Sintilizumab